Epidemiology and adherence to vulvar cancer treatment in western Mexico

Main Article Content

Martha Martin-Garibay
Edith Falconi-Olán
Saul Muñoz-Herrera
Alfonso Cruz-Ramos

Abstract

Objective: To describe the epidemiology, treatment, clinical aspects, and rates of adherence to treat¬ment and follow-up of vulvar cancer in patients treated at the Instituto Jalisciense de Cancerología (IJC) in western Mexico Material y methods: Clinical records of patients with vulvar carcinoma at any clinical stage treated at the IJC during the 2016-2020 period were reviewed. Descriptive statistics were performed with the variables of interest. Results: 53 women with vulvar cancer confirmed by the histopa¬thological study, were studied. At the time of diagnosis, 35.84 % reported a month of evolution; 32.07 %, 6 months; 18.86 %, one year, and 13.2 %, over one year. The tumor size on average was 3,942 cm, and in six patients the size was 1 cm or less. The most frequent initial clinical stage of FIGO was stage III with 37.73 %, followed by stage IB with 28.30 %, and II with 18.86 %. The left labia major is the most commonly affected site, with 22.64 %. 64.15 % of the women abandoned treatment and 83.05 % abandoned follow-up. Conclusions: Squamous cell carcinoma of the vulva is predominant in postmenopausal women with an average age of 66 years. Of 53 cases in 6 years, only 9 continued in follow-up, this implies that most of the patients will have disease progression or even die from it. Most of the patients presented in advanced clinical stages at the time of diagnosis.

Downloads

Download data is not yet available.

Article Details

How to Cite
Martin-Garibay, M., Falconi-Olán, E., Muñoz-Herrera, S., & Cruz-Ramos, A. (2022). Epidemiology and adherence to vulvar cancer treatment in western Mexico. Revista Médica Basadrina, 16(1), 12–17. https://doi.org/10.33326/26176068.2022.1.1512
Section
Artículo original

References

Merlo S. Modern Treatment of Vulvar Cancer. Radiology and Oncology [Internet]. 2020 Sep 22 [cited 2022 Jun 7]; 54(4):371. Available from: /pmc/articles/PMC7585347/ DOI: https://doi.org/10.2478/raon-2020-0053

Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, et al. Vulvar cancer: epidemiology, clinical presentation, and management options. International Journal of Women’s Health [Internet]. 2015 Mar 20 [cited 2022 Jun 7]; 7:305. Available from: /pmc/articles/PMC4374790/ DOI: https://doi.org/10.2147/IJWH.S68979

Siegel DA, Wilson R, Wilkinson EJ, Gargano JW, Watson M, Hernandez BY, et al. Evaluation of the Vulvar Cancer Histology Code Reported by Central Cancer Registries: Importance in Epidemiology. Arch Pathol Lab Med [Internet]. 2017 Jan 1 [cited 2022 Jun 12]; 141(1):139-43. Available from: https://pubmed.ncbi.nlm.nih.gov DOI: https://doi.org/10.5858/arpa.2015-0422-OA

Urgencias en ginecología oncológica [Internet]. [cited 2022 Jun 12]. Available from: https://scielo.isciii.es

Hunter DJS. Carcinoma of the vulva: a review of 361 patients. Gynecol Oncol [Internet]. 1975 [cited 2022 Jun 7]; 3(2):117-23. Available from: https://pubmed.ncbi.nlm.nih.gov/1183864/ DOI: https://doi.org/10.1016/0090-8258(75)90072-4

IMSS. Diagnóstico y tratamiento de cáncer de vagina en el segundo y tercer nivel de atención.

Boyce J, Fruchter RG, Kasambilides E, Nicastri AD, Sedlis A, Remy JC. Prognostic factors in carcinoma of the vulva. Gynecologic Oncology. 1985 Mar 1;20(3):364-77. DOI: https://doi.org/10.1016/0090-8258(85)90218-5

Binder SW, Huang I, Fu YS, Hacker NF, Berek JS. Risk factors for the development of lymph node metastasis in vulvar squamous cell carcinoma. Gynecol Oncol [Internet]. 1990 [cited 2022 Jun 8]; 37(1):9-16. Available from: https://pubmed.ncbi.nlm.nih.gov/1691127/ DOI: https://doi.org/10.1016/0090-8258(90)90298-Y

Gallegos Hernández José Francisco. Cáncer de vulva. Neoplasia poco frecuente con tratamiento evolutivo, recomendaciones para su abordaje diagnóstico-terapéutico en etapas iniciales [Internet]. 2019 [cited 2022 Jun 13]. Available from: http://www.scielo.org.mx

Mathevet P. Approches thérapeutiques actuelles dans les cancers vulvaires. Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 2012 Oct 1; 41(6):519-25. DOI: https://doi.org/10.1016/j.jgyn.2012.03.011

Muigai J, Jacob L, Dinas K, Kostev K, Kalder M. Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices. Oncotarget [Internet]. 2018 [cited 2022 Jun 15]; 9(9):8725-30. Available from: www.impactjournals.com/oncotarget DOI: https://doi.org/10.18632/oncotarget.23848

Kumar N, Ray D, Sharma DN, Pandey R, Lata K, Mishra A, et al. Vulvar cancer: surgical management and survival trends in a low resource setting. [cited 2022 Jun 15]; Available from: https://doi.org/10.1186/s43046-019-0015-y DOI: https://doi.org/10.1186/s43046-019-0015-y